Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tryptophan Methyl Ester. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 2/20 | 0.65 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.58 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.58 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.58 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.58 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.58 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.58 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.58 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.58 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.58 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | HCRTR1 known ✓ | O43613 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptophan Methyl Ester SCHEMBL29398306 | 1.00 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL378072 | 1.00 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL29401004 | 1.00 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL378071 | 1.00 | MEN1 (0.68) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL31291573 | 0.99 | MEN1 (0.67) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL1195735 | 0.99 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL19161138 | 0.99 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL475267 | 0.99 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL122907 | 0.99 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA | |
| Tryptophan Methyl Ester SCHEMBL30180690 | 0.99 | MEN1 (0.70) | MEN1KMT2AKDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569745-A | Spiroindole alkaloid in Polygonum tinctorium, and preparation method and application thereof | 沈阳药科大学 | 2025-03-07 | — | — | CN | claimed |
| CN-114839308-B | Method for detecting L-tryptophan methyl ester hydrochloride in D-tryptophan methyl ester hydrochloride | 江苏天士力帝益药业有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-118666841-A | Indole-tetramic acid compound, preparation and medical application thereof | 中国医学科学院药物研究所 | 2024-09-20 | — | — | CN | claimed |
| CN-117843638-A | Preparation and application of bifunctional molecular compound based on RSL3 induced GPX4 protein degradation | 沈阳药科大学 | 2024-04-09 | — | — | CN | claimed |
| CN-115232130-B | APN and AKT double-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | claimed |
| CN-116574102-A | Preparation method of tadalafil | 广东九明制药有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-113527399-B | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-113999228-B | Synthesis method of tadalafil | 南京卓康医药科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-115232130-A | APN and AKT double-target-point inhibitor and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114839308-A | Method for detecting L-tryptophan methyl ester hydrochloride in D-tryptophan methyl ester hydrochloride | 江苏天士力帝益药业有限公司 | 2022-08-02 | — | — | CN | claimed |
| US-7550479-B2 | Modified Pictet-Spengler reaction and products prepared therefrom | LILLY ICOS LLC (US) | 2009-06-23 | — | — | US | claimed |
| EP-1546149-B1 | MODIFIED PICTET-SPENGLER REACTION AND PRODUCTS PREPARED THEREFROM | LILLY ICOS LLC (US) | 2008-11-26 | — | — | EP | claimed |
| CN-100430395-C | Improved pictet-spengler reaction and products produced therefrom | LILLY ICOS LLC (US) | 2008-11-05 | — | — | CN | claimed |
| US-7223863-B2 | Process for preparing Tadalafil and its intermediate | ALEMBIC LIMITED (IN) | 2007-05-29 | — | — | US | claimed |
| WO-2007052283-A1 | AN IMPROVED PROCESS FOR PREPARING TADALAFIL AND ITS INTERMEDIATE | ALEMBIC LIMITED (IN) | 2007-05-10 | — | — | WO | claimed |
| US-20060258865-A1 | Process for preparing Tadalafil and its intermediate | ALEMBIC LIMITED (IN) | 2006-11-16 | — | — | US | claimed |
| US-20060004203-A1 | Modified pictet-spengler reaction and products prepared therefrom | ICOS CORPORATION | 2006-01-05 | — | — | US | claimed |
| CN-1671706-A | Modified pictet-spengler reaction and products prepared therefrom | LILLY ICOS LLC (US) | 2005-09-21 | — | — | CN | claimed |
| EP-1546149-A1 | MODIFIED PICTET-SPENGLER REACTION AND PRODUCTS PREPARED THEREFROM | Lilly Icos LLC (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004011463-A1 | MODIFIED PICTET-SPENGLER REACTION AND PRODUCTS PREPARED THEREFROM | LILLY ICOS, LLC. (US) | 2004-02-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004203-A1 | Modified pictet-spengler reaction and products prepared therefrom | WEE2, WEE1, WASF2 | TACR1 1540/4885HTR2A 818/4885ADRB1 1993/4885 |
| US-20060258865-A1 | Process for preparing Tadalafil and its intermediate | PDE3B, PDE5A, PDE3A | TACR1 556/4885HTR2A 1073/4885ADRB1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.